BR0007556A - Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos - Google Patents
Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicosInfo
- Publication number
- BR0007556A BR0007556A BR0007556-6A BR0007556A BR0007556A BR 0007556 A BR0007556 A BR 0007556A BR 0007556 A BR0007556 A BR 0007556A BR 0007556 A BR0007556 A BR 0007556A
- Authority
- BR
- Brazil
- Prior art keywords
- tweak
- receptor antagonists
- immune disorders
- treat immune
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Abstract
Patente de Invenção: "ANTAGONISTAS DE TWEAK E DE RECEPTOR DE TWEAK E USO DOS MESMOS PARA TRATAR DISTúRBIOS IMUNOLóGICOS". A presente invenção refere-se a reagentes que modificam a atividade de TWEAK e ao uso dos mesmos como agentes para o tratamento de distúrbios imunológicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11616899P | 1999-01-15 | 1999-01-15 | |
PCT/US2000/001044 WO2000042073A1 (en) | 1999-01-15 | 2000-01-14 | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0007556A true BR0007556A (pt) | 2001-10-23 |
Family
ID=22365656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0007556-6A BR0007556A (pt) | 1999-01-15 | 2000-01-14 | Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos |
Country Status (21)
Country | Link |
---|---|
US (5) | US20020015703A1 (pt) |
EP (1) | EP1141027A1 (pt) |
JP (3) | JP5550799B2 (pt) |
KR (1) | KR20010102978A (pt) |
CN (1) | CN1387538A (pt) |
AU (1) | AU2507700A (pt) |
BR (1) | BR0007556A (pt) |
CA (1) | CA2358684C (pt) |
CZ (1) | CZ20012548A3 (pt) |
EA (1) | EA004590B1 (pt) |
EE (1) | EE200100372A (pt) |
HK (1) | HK1038755A1 (pt) |
HU (1) | HUP0105044A3 (pt) |
IL (1) | IL144007A0 (pt) |
IS (1) | IS5986A (pt) |
MX (1) | MXPA01007163A (pt) |
NO (1) | NO20013340L (pt) |
NZ (1) | NZ529355A (pt) |
SK (1) | SK10042001A3 (pt) |
TR (1) | TR200102021T2 (pt) |
WO (1) | WO2000042073A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
US7001992B2 (en) * | 1997-05-30 | 2006-02-21 | Human Genome Sciences, Inc. | Antibodies to secreted protein HEMCM42 |
WO2000042073A1 (en) * | 1999-01-15 | 2000-07-20 | Biogen, Inc. | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
AU782067B2 (en) * | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
JP2004500844A (ja) | 2000-05-08 | 2004-01-15 | バイオジェン インコーポレイテッド | Tweakアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法 |
EP1317283B1 (en) * | 2000-09-14 | 2011-07-06 | Biogen Idec MA Inc. | Tweak receptor agonists as anti-angiogenic agents |
US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
CA2887716C (en) | 2002-04-09 | 2017-01-24 | Biogen Idec Ma Inc. | Methods for treating tweak-related conditions |
CN101899106A (zh) | 2002-10-29 | 2010-12-01 | 阿纳福公司 | 三聚细胞因子的三聚结合蛋白 |
US7482430B2 (en) | 2003-07-24 | 2009-01-27 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the TWEAK receptor |
WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
EP1566636A1 (en) * | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
WO2006052926A2 (en) * | 2004-11-08 | 2006-05-18 | University Of Maryland, Baltimore | Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
AU2006214179A1 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
US20080286271A1 (en) * | 2005-03-07 | 2008-11-20 | Ashkenazi Avi J | Methods and Compositions for Modulating Tweak and Fn14 Activity |
EP1885388B1 (en) * | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
AU2013200995B2 (en) * | 2005-05-27 | 2016-08-04 | Biogen Ma Inc. | Tweak binding antibodies |
PL2460831T3 (pl) * | 2005-05-27 | 2017-05-31 | Biogen Ma Inc. | Przeciwciała wiążące tweak |
WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
ES2611307T3 (es) * | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
EP2069521A4 (en) * | 2006-10-16 | 2009-12-16 | Biogen Idec Inc | BIOMARKERS OF SCLEROSIS IN PLATE |
ES2411907T3 (es) | 2007-08-03 | 2013-07-09 | Facet Biotech Corporation | Uso terapéutico de anticuerpos antirreceptor TWEAK |
KR20110044992A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | TGF-β 길항제 다중-표적 결합 단백질 |
CN102171247A (zh) * | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
US20130124426A1 (en) * | 2008-10-02 | 2013-05-16 | ecoATM, Inc. | Method And Apparatus For Recycling Electronic Devices |
US8093006B2 (en) * | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
EP2462165B1 (en) | 2009-08-03 | 2016-05-11 | University of Miami | Method for in vivo expansion of t regulatory cells |
WO2011097500A2 (en) | 2010-02-04 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | The tweak/fn14 system regulates skeletal muscle atrophy and regeneration |
US9187564B2 (en) | 2010-10-05 | 2015-11-17 | Hoffmann-La Roche Inc. | Antibodies against human TWEAK and uses thereof |
JP5832559B2 (ja) | 2011-03-10 | 2015-12-16 | オメロス コーポレーション | exvivoにおける加速された抗体進化による抗FN14モノクローナル抗体の生成 |
US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
JP6007310B2 (ja) | 2012-04-05 | 2016-10-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ヒトtweak及びヒトil17に対する二重特異性抗体並びにその使用 |
CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
EP3019874B1 (en) | 2013-07-09 | 2019-08-21 | The Translational Genomics Research Institute | Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14 |
US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
JP2017029001A (ja) * | 2013-12-19 | 2017-02-09 | 国立研究開発法人産業技術総合研究所 | プロテインgの細胞膜外ドメインの新規な改変型タンパク質 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
WO2017131972A1 (en) * | 2016-01-25 | 2017-08-03 | Oxytec Llc | Soil and water remediation method and apparatus for treatment of recalcitrant halogenated substances |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11661360B2 (en) | 2020-06-18 | 2023-05-30 | Wp&E Technologies And Solutions, Llc | System for removing per- and polyfluorinated alkyl substances from contaminated aqueous streams, via chemical aided filtration, and methods of use thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200313A (en) | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
US4921698A (en) | 1984-05-25 | 1990-05-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5073492A (en) | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AT396939B (de) | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0679716A4 (en) | 1993-11-12 | 1999-06-09 | Kenichi Matsubara | GENE SIGNATURE. |
US20030198640A1 (en) | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
ATE354638T1 (de) | 1994-12-13 | 2007-03-15 | Human Genome Sciences Inc | Menschlicher gewebsinhibitor von metalloproteinase-4 |
US6544761B2 (en) | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
WO1998005783A1 (en) * | 1996-08-07 | 1998-02-12 | Biogen, Inc. | A tumor necrosis factor related ligand |
US5858991A (en) | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
EP0977887A2 (en) | 1997-02-12 | 2000-02-09 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
AU7549498A (en) | 1997-06-03 | 1998-12-21 | Protegene Inc. | Human proteins having transmembrane domains and dnas encoding these prot eins |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
DE69839401T2 (de) | 1997-09-18 | 2009-05-07 | Genentech Inc., San Francisco | Dcr3 polypeptid, ein tnfr homolog |
IL135051A0 (en) * | 1997-10-10 | 2001-05-20 | Genentech Inc | Apo-3 ligand polypeptide |
US20020072089A1 (en) | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
US6046381A (en) | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
WO1999059614A1 (en) | 1998-05-20 | 1999-11-25 | Yale University | Modulation of angiogenesis and wound healing |
AU4409099A (en) | 1998-05-29 | 1999-12-13 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
AU772460B2 (en) | 1998-10-16 | 2004-04-29 | Immunex Corporation | Inhibitors of platelet activation and recruitment |
CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
DK1484338T3 (da) | 1998-12-22 | 2007-06-11 | Genentech Inc | Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst |
WO2000042073A1 (en) | 1999-01-15 | 2000-07-20 | Biogen, Inc. | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
ATE348108T1 (de) | 1999-03-08 | 2007-01-15 | Genentech Inc | Methode zum nachweis von tumoren |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
NZ523206A (en) | 1999-08-31 | 2004-12-24 | Genentech Inc | Antibodies that bind to tumor gene sequences |
US6727225B2 (en) * | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
US7495086B2 (en) * | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
AU782067B2 (en) | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
JP4723782B2 (ja) | 2000-01-03 | 2011-07-13 | ティーアール アソシエイツ,エル.エル.シー. | 新規なキメラ蛋白質及び該蛋白質の使用方法 |
US7927602B2 (en) | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
US7074408B2 (en) | 2000-02-25 | 2006-07-11 | Immunex Corporation | Use of integrin antagonists to inhibit angiogenesis |
JP2004500844A (ja) | 2000-05-08 | 2004-01-15 | バイオジェン インコーポレイテッド | Tweakアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法 |
US20040047854A1 (en) | 2001-07-27 | 2004-03-11 | Black Roy A. | Human disintegrin protein |
EP1317283B1 (en) | 2000-09-14 | 2011-07-06 | Biogen Idec MA Inc. | Tweak receptor agonists as anti-angiogenic agents |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
WO2002053737A1 (fr) | 2000-12-28 | 2002-07-11 | Asahi Kasei Kabushiki Kaisha | Gene d'activation de nf-kb |
EP1379132A4 (en) | 2001-03-21 | 2009-07-01 | Human Genome Sciences | HUMAN SECRETED PROTEINS |
US20040203083A1 (en) | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US6756101B2 (en) | 2001-07-16 | 2004-06-29 | Specialty Tapes, Division Of Rsw | Tape for use with high-speed webs and method of use thereof |
WO2003040307A2 (en) | 2001-07-27 | 2003-05-15 | Human Genome Sciences, Inc. | Heteromultimeric tnf ligand family members |
US20040091473A1 (en) | 2001-07-27 | 2004-05-13 | Dubose Robert F. | Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
US20030148314A1 (en) | 2001-08-01 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
CA2887716C (en) * | 2002-04-09 | 2017-01-24 | Biogen Idec Ma Inc. | Methods for treating tweak-related conditions |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
WO2004079014A2 (en) | 2003-03-04 | 2004-09-16 | Arcturus Bioscience, Inc. | Signatures of er status in breast cancer |
US7482430B2 (en) * | 2003-07-24 | 2009-01-27 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the TWEAK receptor |
EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
WO2006052926A2 (en) | 2004-11-08 | 2006-05-18 | University Of Maryland, Baltimore | Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death |
US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
AU2006214179A1 (en) * | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
US20080286271A1 (en) | 2005-03-07 | 2008-11-20 | Ashkenazi Avi J | Methods and Compositions for Modulating Tweak and Fn14 Activity |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
PL2460831T3 (pl) * | 2005-05-27 | 2017-05-31 | Biogen Ma Inc. | Przeciwciała wiążące tweak |
WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
WO2006138219A2 (en) * | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
EP2069521A4 (en) | 2006-10-16 | 2009-12-16 | Biogen Idec Inc | BIOMARKERS OF SCLEROSIS IN PLATE |
MX2010012324A (es) * | 2008-05-15 | 2011-01-14 | Biogen Idec Inc | Anticuerpos anti-fn14 y usos de los mismos. |
WO2010085648A2 (en) | 2009-01-23 | 2010-07-29 | Linda Burkly C | Methods for reducing radiation-induced tissue damage |
MX2011007936A (es) | 2009-01-30 | 2011-08-17 | Biogen Idec Inc | Metodos para regeneracion de tejido pancreatico. |
US9187564B2 (en) * | 2010-10-05 | 2015-11-17 | Hoffmann-La Roche Inc. | Antibodies against human TWEAK and uses thereof |
-
2000
- 2000-01-14 WO PCT/US2000/001044 patent/WO2000042073A1/en not_active Application Discontinuation
- 2000-01-14 MX MXPA01007163A patent/MXPA01007163A/es unknown
- 2000-01-14 TR TR2001/02021T patent/TR200102021T2/xx unknown
- 2000-01-14 EE EEP200100372A patent/EE200100372A/xx unknown
- 2000-01-14 JP JP2000593639A patent/JP5550799B2/ja not_active Expired - Fee Related
- 2000-01-14 AU AU25077/00A patent/AU2507700A/en not_active Abandoned
- 2000-01-14 CN CN00804735A patent/CN1387538A/zh active Pending
- 2000-01-14 EP EP00903307A patent/EP1141027A1/en not_active Withdrawn
- 2000-01-14 KR KR1020017008956A patent/KR20010102978A/ko not_active Application Discontinuation
- 2000-01-14 CZ CZ20012548A patent/CZ20012548A3/cs unknown
- 2000-01-14 HU HU0105044A patent/HUP0105044A3/hu unknown
- 2000-01-14 BR BR0007556-6A patent/BR0007556A/pt not_active Application Discontinuation
- 2000-01-14 EA EA200100780A patent/EA004590B1/ru not_active IP Right Cessation
- 2000-01-14 CA CA2358684A patent/CA2358684C/en not_active Expired - Lifetime
- 2000-01-14 NZ NZ529355A patent/NZ529355A/en not_active IP Right Cessation
- 2000-01-14 SK SK1004-2001A patent/SK10042001A3/sk unknown
- 2000-01-14 IL IL14400700A patent/IL144007A0/xx unknown
-
2001
- 2001-06-29 IS IS5986A patent/IS5986A/is unknown
- 2001-07-05 NO NO20013340A patent/NO20013340L/no not_active Application Discontinuation
- 2001-07-13 US US09/905,810 patent/US20020015703A1/en not_active Abandoned
-
2002
- 2002-01-10 HK HK02100180.8A patent/HK1038755A1/zh unknown
-
2004
- 2004-08-11 US US10/916,141 patent/US7169387B2/en not_active Expired - Lifetime
-
2006
- 2006-10-04 US US11/542,745 patent/US7579001B2/en not_active Expired - Fee Related
-
2009
- 2009-07-20 US US12/506,006 patent/US20100061985A1/en not_active Abandoned
-
2010
- 2010-08-25 JP JP2010188938A patent/JP5592195B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-30 US US13/173,604 patent/US8440189B2/en not_active Expired - Fee Related
-
2013
- 2013-01-17 JP JP2013006243A patent/JP2013075916A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0007556A (pt) | Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos | |
IL132293A0 (en) | Use of lactoferin in the treatment of allergen induced disorders | |
PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
BR0309855A (pt) | Pirazolpiridinas substituìdas com carbamato | |
BRPI0410129A (pt) | uso terapêutico de anticorpos anti-cs1 | |
PT1135153E (pt) | Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares | |
BRPI0316438B8 (pt) | uso de eritropoietina em doenças cardíacas | |
DE69526437D1 (de) | Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens | |
BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
ES2128735T3 (es) | Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas. | |
BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
DE69738613D1 (de) | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten | |
BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
ATE203519T1 (de) | Chinolinderivate als antimalariamittel | |
DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
DK0989973T3 (da) | Chalconer med antiproliferativ aktivitet | |
BR9812660A (pt) | Composições e métodos para tratar distúrbios respiratórios | |
BR9813797A (pt) | Processo para tratar glaucoma de glc1a, e, composição para controlar glaucoma de glc1a. | |
UY26426A1 (es) | Nuevos compuestos | |
ID23175A (id) | Penggunaan benzopiranol untuk mengobati gangguan syaraf | |
BR9808299A (pt) | O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca | |
BR9812531A (pt) | Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica | |
BR9712307A (pt) | Pirazolinonas para o tratamento de potência enfraquecida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN IDEC MA, INC. (US) Free format text: ALTERADO DE: BIOGEN, INC. |
|
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN IDEC MA INC. (US) Free format text: ALTERADO DE: BIOGEN IDEC MA, INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 6A, 7A E 8A ANUIDADE(S). |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O,10,11,24,25 E 32 DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN MA INC. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: BIOGEN MA INC. (US) |